c4therapeutics.com (CCCC): Debt to Equity

Corporate company logo of C4 Therapeutics Corp (CCCC)

The price history of C4 Therapeutics, Inc. (CCCC) demonstrates a standalone debt-to-equity ratio of 0.24. C4 Therapeutics, Inc. (CCCC) generates revenue by licensing an innovative platform designed to combat severe oncological diseases. Its technology stack leverages AI and robotics to rapidly identify protein degradation formulas. Meanwhile, the business faces a liquidity shortage and is depleting reserves on costly research.

CCCC: C4 Therapeutics Total Debt to Equity Ratio 07/04/2022 - 10/31/2026

Comprehensive metric breakdowns and analytics for C4 Therapeutics Corp (CCCC)

- price and consensus price forecast:
Price Chart C4 Therapeutics|CCCC - Average Forecast Price
- stock exchange capitalization data:
Market Value C4 Therapeutics|CCCC - Business Value
- company book value details:
Book Value per Share C4 Therapeutics|CCCC - Company Net Assets|Market Value to Book Value Ratio c4therapeutics.com|CCCC - Company Assets
- debt obligations and liquidity statistics:
Debt to Equity C4 Therapeutics, Inc.|CCCC - Long-Term Debt to Equity|Short-Term Debt to Equity C4 Therapeutics, Inc.|CCCC - Company Cumulative Debt|Debts to Book Capitalization C4 Therapeutics|CCCC - Long-Term Indebtedness|Company Current Liabilities C4 Therapeutics|Quick Liquidity Indicator c4therapeutics.com
- earnings and valuation multiples information:
CCCC - Final Profit
Fundamental company analysis:C4 Therapeutics, CCCC
Core merchandise of C4 Therapeutics, Inc.

The analyst assesses the credit quality of C4 Therapeutics, Inc. (CCCC) through its liability structure. Planned laboratory utilization and partners' readiness for drug launches confirm the business's operational stability. This change in the debt-to-equity ratio measures the proportion of external debt relative to owner assets. A low ratio minimizes risks during rate hikes, creating a financial buffer. Investors should use this indicator to monitor leverage sustainability.

Competitors of C4 Therapeutics, Inc. (CCCC)

Debt to Equity Genmab|Debt to Capital Exelixis Inc EXEL|Debt to Equity Nuvalent Corp (NUVL)|Kymera Corp - Debt to Equity Ratio|Total Debt to Capital IDYA (IDEAYA Biosciences)|ELVN - Total Debt to Equity Ratio|ORIC - Debt to Equity|Debt to Capital Relay Therapeutics Inc|Nurix Pharma (NRIX) - Debt to Equity|TYRA (Tyra Corp) - Debt to Equity|Debt to Equity Verastem, Inc.|Debt to Capital monterosatx.com GLUE|Total Debt to Capital CGEM|Immuneering Corp (IMRX) - Debt to Capital Ratio|Black Diamond Therapeutics Inc. - Total Debt to Equity Ratio|Repare Therapeutics Inc (RPTX) - Debt to Capital|PMVP: Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio KPTI (Karyopharm Therapeutics)|PPCB (propanc.com) - Total Debt to Equity Ratio|BGMS: Aggregate Debt to Capital|AADI (Aadi Bioscience Inc) - Total Debt to Capital|Total Debt to Capital Aileron|Debt to Equity Blueprint Medicines (BPMC)|GLYC (glycomimetics.com) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital SWTX (SpringWorks Therapeutics, Inc.)